Pfizer Breaks With Biosimilars In China Through WuXi Bio Deal

Pfizer China To Also Offload Manufacturing Site In Hangzhou

 
• By Dean Rudge

Pfizer has announced plans to put a lid on its biosimilars programs in China, while agreeing the sale of its manufacturing site in Hangzhou.

China globe
The agreement for the biologics site in Hangzhou is expected to close in the first half of 2021 • Source: Shutterstock

More from Biosimilars

More from Products